Dismissing Requests of World’s Gelatin Makers, FDA Asks USP to Add Tests for Melamine to Monograph
This article was originally published in The Gold Sheet
Undeterred by arguments from gelatin manufacturers that there is no economic motivation to put melamine in gelatin, FDA asks USP to require additional testing for the potential adulterant.
You may also be interested in...
China’s latest product safety scandal could have far-reaching implications, potentially even disrupting China's tendering system for essential medicines.
Which excipients might be vulnerable to melamine substitution? FDA provides its list of 23 at-risk excipients and recommends specific steps for safeguarding them.
Pharmaceutical identity crisis arises after ingredients are mimicked by cheap, deadly substitutes. Chemical sleuths tell how they found the melamine cyanurate, oversulfated chondroitin sulfate and diethylene glycol that were hidden in pet food, heparin and cold remedies. Efforts to better identify drug ingredients takes on new urgency with melamine spreading to infant formula and rumors of possible attempts to devise a new heparin adulterant. As instrumental compendial tests are added to monographs, industry, legislators, regulators and compendial organizations grapple with broader implications of this new type of adulteration. U.S. Pharmacopeia leadership talks about establishing a massive standardized spectral library that could be accessed using remote analyzers to instantly identify ingredients, impurities and adulterants.